PTNTCorgi IP Licensing & Royalties ETF

Grow my moneyNewRanked #2,488 of 2,954 in this goal

Seeks capital appreciation through investment in companies that derive material revenue from intellectual property licensing, royalties, and franchising.

By Corgi Funds · Launched 2026

Annual Cost

0.35%

#1,660 of 5,589 · low cost

Fund Size

$1M

#5,432 of 5,589 · small

Return (1Y)Goal

N/A

Track Record

1 month

#5,462 of 5,589 · young

Performance

Total-return NAV · USD

Growth of $10,000

$10,498+5.0%

Total-return NAV, USD. Net of fund fees, before tax.

What's inside

How Beacon categorizes this fund

Asset class

Equity

Region

Global

Strategy

Active selection

Focus

Royalties, Pharmaceuticals

What it actually holds

By weight

Concentration

Top 10 holdings = 56.0% of fundmoderately concentrated

Qualcomm IncQCOM

8.5%

McDonald's CorpMCD

7.4%

ARM Holdings PLC ADRARM

6.8%

Netflix IncNFLX

6.3%

International Business Machines CorpIBM

5.7%

Cadence Design Systems IncCDNS

5.0%

The Walt Disney CoDIS

4.5%

Synopsys IncSNPS

4.2%

Yum Brands IncYUM

4.0%

Royalty Pharma PLC Class ARPRX

3.7%

Asset allocation

Stocks

98.1%

Cash

1.8%

Other

0.1%

By sector

Technology

48.6%

Communication

21.0%

Consumer Cyclical

20.4%

Healthcare

7.2%

Industrials

2.8%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years

Volatility (1Y)

N/A

Max drawdown

-6.9%Mild

Worst peak-to-trough loss

Sharpe (3Y)

Unavailable

Needs 3+ years of history

Sortino (3Y)

Not yet

Needs 3+ years of history

Listing

Exchange: Cboe BZX, New York Stock Exchange

Full fund details

Objective: Seeks capital appreciation through investment in companies that derive material revenue from intellectual property licensing, royalties, and franchising.
Strategy: Actively managed; invests at least 80% of net assets in common stock of U.S. and foreign companies (any market cap, including ADRs) that derive material revenue from IP licensing, patent and technology royalties, content and franchise royalties, brand/trademark licensing, or pharmaceutical royalty streams. Adviser combines bottom-up fundamental analysis with thematic and quantitative screening. Non-diversified.
Inception date: May 5, 2026
Fund family: Corgi Funds